Minerva Neurosciences | NERV - Current Liabilities


Minerva Neurosciences reported $2.67M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Adma Biologics USD 56.49M 18.45M Sep/2025
ALKERMES USD 543.44M 69.08M Dec/2025
Alterity Therapeutics Limited AUD 4.38M 849.82K Jun/2023
AstraZeneca USD 30.62B 3.44B Dec/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Cipla INR 62.97B 8.13B Sep/2025
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 20.28M 300K Sep/2025
CSL USD 4.61B 207M Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Grifols EUR 2.53B 182.67M Sep/2025
Halozyme Therapeutics USD 177.09M 660.14M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
J&J USD 54.13B 3.26B Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Minerva Neurosciences USD 2.67M 143K Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novartis USD 32B 286M Sep/2025
Novavax USD 429.87M 40.73M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Takeda JPY 2.61T 470.53B Dec/2025
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025